A Montreal study, to which research member Dr. Moishe Liberman contributed, shows that a drug increases the chances of survival for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.
The drug, which restores the anti-tumor immune response, is combined with chemotherapy and administered before surgery.
The results of this study were published in the prestigious New England Journal of Medicine.
Investment for a 3D printing park
24 January 2022
The Institut du cancer de Montréal (ICM) is proud to have contributed to the implementation of a 3D printing park […]
Dr. David Roberge: Appointment to the Canadian Association of Radiation Oncology
17 January 2022
The Institute would like to acknowledge the appointment of Dr. David Roberge as President-Elect of the Canadian Association of Radiation […]